EMA Withdrawn: Xigris (drotrecogin alfa (activated)) — Eli Lilly Nederland B.V.

View source ↗

Summary

The EMA withdrew Xigris (drotrecogin alfa activated) from the market for sepsis with multiple organ failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Organ Failure
• Sepsis

Drugs mentioned

• Xigris (Drotrecogin alfa (activated))

Snippet

Status: Withdrawn. Therapeutic area: Sepsis;Multiple Organ Failure. MAH: Eli Lilly Nederland B.V.. Decision date: 28/11/2011